Indivior settles patent case with Actavis, boosting share price

Indivior shares (LSE: INDV) jumped after the company said it settled a patent dispute with Actavis Laboratories, allowing the rival to sell a generic film to treat opioid addiction from 2025.

The FTSE 250 firm granted Actavis a license to a key patent, permitting it to introduce copycat buprenorphine and naloxone treatments in the US from January 2025. Indivior shares initially rose over 4% on news of the deal before paring some gains.

Read More News:
Tortilla shares tumble as high street sites struggle

The settlement ends the litigation over Actavis’s generic version of Indivior’s sublingual film to combat opioid addiction. Despite ceding ground on patents, Indivior continues to focus on expanding access to evidence-based addiction treatments globally.

With drugs aimed at opioid use disorder, the company strives to redefine addiction as a chronic illness requiring ongoing care. The deal embodies Indivior’s commitment to advancing innovative solutions for substance use disorders.

Indivior shares are down 35% year to date.